Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Rhea-AI Summary

Aclarion (Nasdaq: ACON) was named a finalist on Oct 7, 2025 for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH in the Rising Star - Clinical Diagnostic Device category.

Nociscan is described as a SaaS platform that transforms MR spectroscopy signals into objective biomarkers to noninvasively distinguish painful from non-painful lumbar discs, supporting more personalized treatment plans. The company cites an estimated 266 million people worldwide living with chronic low back pain and notes it was selected from more than 1,800 submissions.

Company recognized for breakthrough Nociscan solution for chronic low back pain, one of the most widespread health challenges

BROOMFIELD, Colo., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its selection as a finalist in the Rising Star - Clinical Diagnostic Device category for the prestigious 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH.

This recognition highlights the company's aim to make Nociscan the gold standard in identifying sources of low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and non-painful discs in the lumbar spine. By transforming MR spectroscopy signals into objective biomarkers demonstrated to be associated with disc pain, Nociscan provides actionable information that enables physicians to develop more personalized treatment plans for patients. An estimated 266 million people across the globe live with chronic low back pain.

“We are truly honored to be recognized as a finalist by the Digital Health Hub Foundation, which is a testament not only to the innovation of our team today but also to the vision and determination that have guided Aclarion from the very beginning,” said Brent Ness, CEO of Aclarion. “This recognition reinforces our mission to make Nociscan more broadly available to the millions of people worldwide suffering from chronic low back pain.”

The Digital Health Hub Foundation Awards honor organizations making strides in improving healthcare speed, efficiency and equity with their digital innovations. Being named a finalist from a pool of more than 1,800 submissions reflects Aclarion’s commitment to driving meaningful change in the healthcare landscape.

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: info@aclarion.com

About The Digital Health Hub Foundation

The Digital Health Hub Foundation’s mission is to help the world’s next best innovative healthcare companies scale and grow. Founded in 2017, on the campus of UCSF in San Francisco, our now 30,000 member community consists of thousands of early-to late-stage healthcare companies and highly qualified healthcare industry providers, payors, experts, mentors, investors, clinicians and researchers who participate in our annual awards ceremony where we bring together the industry to honor and validate the best of the best and celebrate the technological advances in healthcare and the impact it has.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.  For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contacts:

Jessica Starman
media@elev8newmedia.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/68562304-df4c-4e10-8def-c546b689f922

FAQ

What did Aclarion announce about the Digital Health Awards on Oct 7, 2025?

Aclarion announced it was selected as a finalist in the Rising Star - Clinical Diagnostic Device category for the 2025 Digital Health Hub Foundation Awards at HLTH.

How does Aclarion's Nociscan platform identify sources of low back pain (ACON)?

Nociscan converts MR spectroscopy signals into objective biomarkers that the company says help distinguish painful versus non-painful lumbar discs noninvasively.

How many submissions competed for the 2025 Digital Health Hub Foundation Awards?

The company reported the finalist selection came from a pool of more than 1,800 submissions.

How many people worldwide are estimated to live with chronic low back pain according to Aclarion?

Aclarion cites an estimate of 266 million people globally living with chronic low back pain.

Where can patients or clinicians find a Nociscan center operated by Aclarion?

Aclarion directs users to its site map to find a Nociscan center and offers an email contact at info@aclarion.com for more information.